Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD

Inflammatory Bowel Diseases

Volumn 19, Issue 2, 2013, Pages 418-422

  Naganuma, Makoto ^a,b,c   Nagahori, Masakazu ^a   Fujii, Toshimitsu ^a   Morio, Junko ^a   Saito, Eiko ^a   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Biologics; Immunomodulators; Inflammatory bowel disease; Serological test for virus

Indexed keywords

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; COLITIS; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MEASLES; MUMPS; MUMPS VIRUS; PRIORITY JOURNAL; RUBELLA; ULCERATIVE COLITIS; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MEASLES VIRUS; MENTAL RECALL; MIDDLE AGED; MUMPS VIRUS; PROSPECTIVE STUDIES; RUBELLA VIRUS; VACCINATION; YOUNG ADULT;

EID: 84876413804     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.23027     Document Type: Article

References (16)

1. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis. 2009;3: 47-91.
2. Kollas G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 2002;13:315-321.
3. Duchet-Niedziolka P, Coutsinos Z, Hanslik T, et al. Anti-TNFa therapy and vaccine of adults. Joint Bone Spine. 2007;74:563-565.
4. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in case with HIV infection. J Med Assoc Thai. 2002;85:131-134.
5. Schrauder A, Henke-Gendo C, Seidemann K, et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet. 2007;369:1232.
6. Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant. 2006;6:565-568.
7. Gross TP, Khurana RK, Higgins T, et al. Vaccine-associated poliomyelitis in a household contact with Netherton's syndrome receiving long-term steroid therapy. Am J Med. 1987;83:797-800.
8. Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1417-1423.
9. Van Assche G, D'Haens G, Noman M, et al. Randomized double-blind comparison of 4 mg/kg/day versus 2 mg/kg/day intravenous cyclosporin in severe ulcerative colitis. Gastroenterology. 2003;125:1025-1031.
10. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255-1262.
11. Byrne L, Brant L, Reynolds C, et al. Seroprevalence of low rubella IgG antibody levels among antenatal women in England tested by NHS Blood and Transplant: 2004-2009. Is rubella susceptibility increasing? Vaccine. 2012;30:161-167.
12. Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan. J Crohn's Colitis. 2011;5:317-323.
13. Komiyama T, Yajima T, Kubota R, et al. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. J Crohn's Colitis. 2008;2:315-321.
14. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483.
15. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63-101.
16. Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med. 2006;100:1291-1293.